高级检索
当前位置: 首页 > 详情页

Impaired secretion of glucagon-like peptide 1 during oral glucose tolerance test in patients with newly diagnosed type 2 diabetes mellitus

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Endocrinol & Metab, Wuhan 430074, Peoples R China [2]Hosp Xinjiang Prod & Construct Corps, Dept Endocrinol & Metab, Xinjiang, Peoples R China [3]Shihezi Univ, Affiliated Hosp 1, Sch Med, Dept Endocrinol & Metab, Shihezi, Xinjiang, Peoples R China
出处:
ISSN:

摘要:
Objectives: To assess glucagon-like peptide 1 (GLP-1) secretion after oral glucose tolerance tests (OGTTs) in subjects with newly diagnosed type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), and normal glucose tolerance (NGT) to clarify changes in GLP-1 secretion during the course of T2DM. Methods: In this cross sectional study, 80 subjects were divided into the NGT, IGT, and T2DM groups after undergoing a 75 g OGTT from March to December 2014 at the School of Medicine, First Affiliated Hospital, Shihezi University, Xinjiang, China. Plasma total GLP-1 was measured at 0, 30, 60, 120, and 180 minutes. Homeostasis model assessment of insulin resistance (HOMA-IR), islet beta-cell function (HOMA-beta), Gutt index, Matsuda index, incremental GLP-1 (Delta GLP-1), and areas under the curves of GLP-1 (AUC(glp-1)), glucose (AUC(g)), and insulin (AUC(ins)) were calculated. Results: Plasma total GLP-1 at 30-120 minutes and Delta GLP-1 at 30-120 minutes were lower in the T2DM group than in the IGT and NGT groups (p<0.05). Peak GLP-1 levels were 35% lower in the T2DM group than in the NGT group. Plasma total GLP-1, Delta GLP1, and AUC(glp-1) correlated negatively with HOMA-IR and AUC(g), and positively with HOMA-beta, Gutt index, Matsuda index, and AUC(ins) (p<0.05). Conclusion: The GLP-1 secretion after 75 g OGTT was impaired in newly diagnosed T2DM patients, inversely proportional to IR and hyperglycemia, and positively correlated with beta-cell function and insulin sensitivity.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2014]版:
Q4 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Endocrinol & Metab, Wuhan 430074, Peoples R China [3]Shihezi Univ, Affiliated Hosp 1, Sch Med, Dept Endocrinol & Metab, Shihezi, Xinjiang, Peoples R China
通讯作者:
通讯机构: [3]Shihezi Univ, Affiliated Hosp 1, Sch Med, Dept Endocrinol & Metab, Shihezi, Xinjiang, Peoples R China [*1]Shihezi Univ, Affiliated Hosp 1, Sch Med, Shihezi, Xinjiang, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:0 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)